Key facts
- This page summarizes Robert James Wills's Form 4 filing for Oncternal Therapeutics, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Apr 2024, 20:38.
Robert James Wills - 08 Apr 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 08 Apr 2024
- Net transaction value
- +$27,655
- SEC form
- 4
- Accepted by SEC
- 10 Apr 2024, 20:38:22 UTC
- Prior SEC filing
- 01 Apr 2024
- Next SEC filing
- 24 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Chase C. Leavitt, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert James Wills filed Form 4 for Oncternal Therapeutics, Inc. on 10 Apr 2024.
Change
- Previous filing in this sequence was filed on 01 Apr 2024.
- Current net transaction value: +$27,655.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONCT
transaction
Common Stock
Purchase
- Transaction value
- $27,655
- Shares
- +3,086
- Change %
- +45%
- Price
- $8.96
- Shares after
- 10,000
- Date
- 08 Apr 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The common stock purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, but the reporting person previously paid the Issuer the full amount of the profit realized in connection with the short swing transaction. No further amounts are required to be disgorged.
Footnote F2
The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.76 to $9.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above.